Sep 30, 2021
*suddenly remembers you are very good in exacts and you've been having trouble because you got lazy*
seen from Russia
seen from Russia
seen from Russia
seen from China
seen from Russia
seen from Russia
seen from Sweden
seen from China
seen from United Kingdom
seen from United States
seen from China
seen from Netherlands
seen from China
seen from United States
seen from France
seen from Türkiye
seen from China
seen from Sweden
seen from Malaysia
seen from China
*suddenly remembers you are very good in exacts and you've been having trouble because you got lazy*
Exact Sciences Corp. (EXAS): Q4 2019 Earnings Snapshot
Exact Sciences Corp. (EXAS): Q4 2019 Earnings Snapshot
— Exact Sciences Corp. (NASDAQ: EXAS) reported Q4 2019 earnings of $0.54 per share, vs. a loss of $0.35 expected.
— Total revenues were $295.6 million, vs. $283 million expected.
— Screening revenues increased 60% to $229.4 million.
— Cologuard test volume rose 63% to 477,000.
— Average Cologuard recognized revenue per test was $481.
— Average Cologuard cost per test was $123.
View On WordPress